跳至主要内容
临床试验/NCT04283266
NCT04283266已完成不适用

Impact of a Synbiotic Containing Fructo-oligosaccharides and Bifidobacteria on Stool Frequency and Biological Markers in Middle-aged Adults: a Randomized, Double-blind, Placebo-controlled Clinical Trial

Vesale Pharmaceutica0 个研究点目标入组 27 人开始时间: 2016年6月12日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
27
主要终点
intestinal transit

研究概览

简要总结

The aim of the study is to evaluate the impact of a synbiotic containing fructo-oligosaccharides (FOS) and Bifidobacteria (VES002 LMG P-28149) on intestinal transit in middle-aged subjects characterized by a low number of defecations per week.

详细描述

Middle-aged subjects, who met ROME III criteria for constipation, received daily two sachets of either synbiotic or for 5 days, then they received daily 1 sachet for the next 25 days.

The primary endpoint of this trial is to evaluate the effect of supplementation in synbiotic containing fructo-oligosaccharides (FOS) and Bifidobacteria (VES002 LMG P-28149) on intestinal transit in middle-aged subjects characterized by a few bowel movements per week. The secondary endpoints are to evaluate both clinical criteria such as changes in stool appearance, quality of life and mood, relief and satisfaction of participants; and biological criteria such as changes in markers of gut function, low-grade chronic inflammation markers and gut microbiota composition. The safety of product use and compliance are also evaluated

Synbiotic group. The dietary supplement under study was composed of fructo-oligosaccharides - FOS: 4.95 gr / sachet and Bifidobacterium animalis lactis: VES002 (LMG P-28149): 5 billion / sachet. Sachets of powder were diluted in a in 200 ml of water at room temperature to be taken before breakfast. Doses were 2 sachets per day for the first 5 days and then 1 sachet per day for the next 25 days.

Placebo group. The placebo looked strictly identical to the synbiotic and contained only excipients (60% maltodextrin / 40% sucrose). Sachets of powder were diluted in a in 200 ml of water at room temperature to be taken before breakfast. Doses were 2 sachets per day for the first 5 days and then 1 sachet per day for the next 25 days.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
50 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Free and informed consent
  • Healthy male and female aged 50-70 years
  • Patient with ≥1 and ≤3 bowel movements per week in the month before the selection visit and in the two weeks before the enrolment visit.
  • At least one in four bowel movements had to involve hard faeces or separate lumps of faeces (Bristol scale class 1 in the three months before enrolment).

排除标准

  • Subjects who, in the 30 days before the selection visit or at the time of the visit, had taken drugs, dietary supplements or any foodstuff enhanced in or containing substances, bacteria or yeasts that might have an effect on primary and secondary outcomes.
  • Such products were also prohibited throughout the study.
  • Subjects on a particular diet or who were under medical treatment that in the investigator's viewpoint might interfere with the evaluation of the study criteria
  • Subjects who drink more than three glasses of wine a day or two 25 cl glasses of beer a day, or one glass of spirits per day.
  • Subjects who drink more than five cups of coffee per day;
  • Subjects with a body mass index (BMI) of more than 30,
  • Subjects with type I or II diabetes,
  • Subjects with constipation attributable to an organic or anatomical cause;
  • Subjects with a history of chronic or inflammatory gastro-intestinal disease;
  • Subjects with a history of digestive tract operation including bariatric surgery;

结局指标

主要结局

intestinal transit

时间窗: daily evaluation (day-14 to day 30)

stool frequency and consistency were investigated through daily self-assessment using the Bristol Stool Form Scale (BSFS). The BSFS classifies stools into 7 categories, including type 1, separate hard lumps, like nuts; type 2, sausage-shaped, but lumpy; type 3, like a sausage but with cracks on the surface; type 4, like a sausage or snake, smooth and soft; type 5, soft blobs with clear-cut edges; type 6, fluffy pieces with ragged edges, a mushy stool; type 7, watery, no solid pieces

次要结局

  • plasma inflammatory markers (pg/ml)(day 0 and day 30)
  • evaluation of quality of life(day 0 and day 30)
  • plasma gut peptides (pg/ml)(day 0 and day 30)
  • abdominal pain and intestinal discomfort(day -14 and day 30)
  • stool consistency(daily evaluation (day-14 to day 30))
  • mood(daily evaluation (day-14 to day 30))
  • microbiota composition(day 0 and day 30)

研究者

发起方
Vesale Pharmaceutica
申办方类型
Industry
责任方
Sponsor

相似试验